IceCure Medical Ltd
IceCure Medical Ltd (ICCM) Stock Overview
Explore IceCure Medical Ltd’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
57.7M
P/E Ratio
-3.81
EPS (TTM)
$-0.28
ROE
-1.82%
ICCM Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of IceCure Medical Ltd (ICCM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $0.73.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -3.81 and a market capitalization of 57.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Analyst Recommendations
Price Targets
Company Profile
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Eyal Shamir
64
7 Ha’Eshel Street, Caesarea
2021